---
layout: post
title: 'New Drug Approvals 2013 - Pt. IV - Ospemifene (OSPHENAÂ®) '
date: '2013-03-22T12:53:00.000Z'
author: Ramesh
tags:
- Oral Drugs
- Small Molecule Drugs
- 2013 New Drugs
- Black Box Warning Drugs
modified_time: '2013-03-22T12:53:23.223Z'
thumbnail: http://3.bp.blogspot.com/-UgXEoECIWVE/UUcXEiFd4NI/AAAAAAAAAGY/2KFeo45qkbg/s72-c/Screen+Shot+2013-03-18+at+13.14.25.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3459892115297539442
blogger_orig_url: http://chembl.blogspot.com/2013/03/new-drug-approvals-2013-pt-iv.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.osphena.com/images/logo.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://www.osphena.com/images/logo.png" /></a></div>
<div class="separator" dir="rtl" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,0,0,2,0,1,0,0,1,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="41" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,0,0,2,0,1,0,0,1,1" width="400" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
</div>
<div style="text-align: center;">
<b><br /></b></div>
<div style="text-align: center;">
<b>ATC Code:</b> Not Assigned</div>
<div style="text-align: center;">
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Ospemifene">Ospemifene</a></div>
<br />
<div style="text-align: justify;">
<span style="font-family: inherit;">On February 26, FDA approved <a href="http://en.wikipedia.org/wiki/Ospemifene">Ospemifene</a> (<i>Trade Name</i>: <a href="http://www.osphena.com/">OSPHENA</a>,&nbsp;<i>PubChem</i>:&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3036505">CID 3036505</a>,&nbsp;<i>ChEMBL</i>:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2105395">CHEMBL210</a><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2105395">5395</a>, <i>ChemSpider</i>:&nbsp;<a href="http://www.chemspider.com/Chemical-Structure.2300501">2300501</a>) for the treatment of moderate to severe <a href="http://en.wikipedia.org/wiki/Dyspareunia">Dyspareunia</a>&nbsp;-&nbsp;symptom of vulvular and vaginal atrophy due to menopause.</span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><a href="http://en.wikipedia.org/wiki/Dyspareunia">Dyspareunia</a>, is pain during or after sexual intercourse. It can affect men, but is significantly more common in women, affecting up to one-fifth of women at some point in their lives. Women with dyspareunia may have pain in the vagina, clitoris or labia. This may be due to&nbsp;medical or psychological causes. There are numerous medical causes of Dyspareunia, like : <a href="http://www.vaginismus.com/faqs/vaginismus-questions/what-is-vaginismus/">Vaginismus</a>, <a href="http://en.wikipedia.org/wiki/Pelvic_inflammatory_disease">Pelvic Inflammatory Disease</a>, Genital or Pelvic Tumors, <a href="http://www.vaginismus.com/community/other-sexual-paindyspareunia-resources/urethritis/">Urethritis</a>, <a href="http://www.vaginismus.com/community/other-sexual-paindyspareunia-resources/urethritis/">Urinary Tract Infection</a>, <a href="http://www.vaginismus.com/community/other-sexual-paindyspareunia-resources/vaginitis/">Vaginal Atrophy</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001894/">Vaginal Dryness</a>, <a href="http://en.wikipedia.org/wiki/Vulvar_cancer">Vulvar Cancer</a>, <a href="http://en.wikipedia.org/wiki/Postpartum">Childbirth Trauma</a> (postpartum), Skin Conditions (Lichen Sclerosus, Lichen Planus, Eczema, Psoriasis), <a href="http://www.vaginismus.com/community/other-sexual-paindyspareunia-resources/female-genital-mutilation-fgm/">Female Genital Mutilation</a>, <a href="http://www.vaginismus.com/community/other-sexual-paindyspareunia-resources/endometriosis/">Endometriosis</a>&nbsp; - many of which can be treatable.</span><br />
<span style="font-family: inherit;"><br /></span></div>
<div style="text-align: justify;">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.cancer.gov/PublishedContent/Images/images/documents/2be76a12-8f47-4da5-83ce-3a6b6ec0a179/slide15.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: inherit;"><img border="0" height="300" src="http://www.cancer.gov/PublishedContent/Images/images/documents/2be76a12-8f47-4da5-83ce-3a6b6ec0a179/slide15.gif" width="400" /></span></a></div>
<span style="font-family: inherit;"><br /></span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;">Ospemifene is a novel <i>selective estrogen receptor modulator</i> (<a href="http://en.wikipedia.org/wiki/Selective_estrogen_receptor_modulator">SERM</a>) - class of compounds that acts on <a href="http://en.wikipedia.org/wiki/Estrogen_receptor">Estrogen Receptors</a>&nbsp;(ER's). <a href="http://en.wikipedia.org/wiki/Selective_estrogen_receptor_modulator#Members_and_uses">SERM's</a>&nbsp;has a&nbsp;distinguishing&nbsp;characteristic&nbsp;that makes them different from pure&nbsp;receptor<i> agonists</i>&nbsp;and&nbsp;<i>antagonists,&nbsp;</i>which is - that their <i><a href="http://en.wikipedia.org/wiki/Mechanism_of_action">mode of action</a></i> is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues (<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=ospemifene">Pub-Med</a>).&nbsp;Ospemifene is an <a href="http://en.wikipedia.org/wiki/Estrogen">Estrogen</a> agonist/antagonist with tissue selective effects. Its biological actions are mediated through binding to <a href="http://en.wikipedia.org/wiki/Estrogen_receptor">Estrogen Receptors</a>&nbsp;(<i>Short Name</i>: ER, ESR;&nbsp;<i>UniProt</i>:&nbsp;<a href="http://www.uniprot.org/uniprot/Q92731">Q92731</a>&nbsp;and&nbsp;<a href="http://www.uniprot.org/uniprot/P03372">P03372</a>;&nbsp;<i>ChEMBL</i>:&nbsp;<a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL2093866">CHEMBL2093866</a>). This binding results in <i>activation</i> of estrogenic pathways in some tissues (<i>agonism</i>) and <i>blockade</i> of estrogenic pathways in others (<i>antagonism</i>).</span><br />
<span style="font-family: inherit;"><br /></span></div>
<div style="text-align: justify;">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.qiagen.com/geneglobe/static/images/Pathways/Estrogen%20Pathway.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: inherit;"><img border="0" height="400" src="http://www.qiagen.com/geneglobe/static/images/Pathways/Estrogen%20Pathway.jpg" width="287" /></span></a></div>
<span style="font-family: inherit;"><br /></span>
<span style="font-family: inherit;"><a href="http://en.wikipedia.org/wiki/Selective_estrogen_receptor_modulator#Mechanism_of_action">Mechanism of action</a> of SERM's is of mixed agonism/antagonism which may differ depending on the chemical structure, but, for at least for some SERM's, it appears to be related to -</span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><i>1.</i> The ratio of <a href="http://en.wikipedia.org/wiki/Coactivation_(Transcription)">co-activator</a> to <a href="http://en.wikipedia.org/wiki/Corepressor_(genetics)">co-repressor</a> proteins in different cell types.</span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><i>2.</i> The conformation of the estrogen receptor induced by drug binding, which in turn determines how strongly the drug/receptor complex recruits co-activators (resulting in an <i>agonist</i> response) relative to co-repressors (resulting in <i>antagonism</i>).</span></div>
<span style="font-family: inherit;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-UgXEoECIWVE/UUcXEiFd4NI/AAAAAAAAAGY/2KFeo45qkbg/s1600/Screen+Shot+2013-03-18+at+13.14.25.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: inherit;"><img border="0" height="345" src="http://3.bp.blogspot.com/-UgXEoECIWVE/UUcXEiFd4NI/AAAAAAAAAGY/2KFeo45qkbg/s400/Screen+Shot+2013-03-18+at+13.14.25.png" width="400" /></span></a></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><br /></span>
<span style="font-family: inherit;">The protein sequences of human&nbsp;ER-alpha (<i>ESR1)</i>&nbsp;and ER-beta (<i>ESR2)&nbsp;</i>can be downloaded in fasta format from the link&nbsp;<a href="http://www.uniprot.org/uniprot/?query=ESR1_HUMAN+OR+ESR2_HUMAN&amp;format=fasta">here</a>. (<i>courtesy UniProt</i>)</span></div>
<span style="font-family: inherit;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-0c2d6hBXE-4/UUcF4ERYWnI/AAAAAAAAAGE/2vDpP_ta19k/s1600/1377665.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: inherit;"><img border="0" height="320" src="http://3.bp.blogspot.com/-0c2d6hBXE-4/UUcF4ERYWnI/AAAAAAAAAGE/2vDpP_ta19k/s320/1377665.png" width="317" /></span></a></div>
<div class="separator" style="clear: both; text-align: justify;">
</div>
<div class="separator" style="clear: both;">
<i><span style="font-family: inherit;"><br /></span></i></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><i>Compound Name&nbsp;</i>: Z-2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><i>Canonical SMILES&nbsp;</i>: OCCOc1ccc(cc1)\C(=C(\CCCl)/c2ccccc2)\c3ccccc3</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><i>Standard InChI&nbsp;</i>: InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><i>Standard InChI Key&nbsp;</i>: LUMKNAVTFCDUIE-VHXPQNKSSA-N</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><br /></span></div>
<div class="separator" style="clear: both; text-align: justify;">
<span style="font-family: inherit;"><span style="text-align: left;">Ospemifene, an ER agonist/antagonist, has a molecular weight of 378.9. The recommended dosage is 60 mg, available in the form of table for oral administration. After single dosage of&nbsp;</span>Ospemifene u<span style="text-align: left;">nder fasted conditions, m</span>ean Cmax and AUC (0 to infinity) were 533 ng/mL and 4165 ng.hr/mL, respectively.&nbsp;With a high fat/high diet, mean Cmax and AUC (0 to infinity) were 1198 ng/mL and 7521 ng.hr/mL, respectively. It is highly bound to serum proteins ( &gt;99%) with apparent volume of distribution of 448 L. Ospemifene primarily undergoes metabolism via CYP3A4, CYP2C9 and CYP2C19 and the major metabolite was <i>4-hydroxyospemifene.</i>&nbsp;Clearance of ospemifene was 9.16 L/hr and terminal half-life was 26 hrs.&nbsp;Following an oral administration of ospemifene, approximately 75% and 7% of the dose was excreted in feces and urine, respectively.</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><br /></span></div>
<div class="separator" style="clear: both; text-align: justify;">
<span style="font-family: inherit;">Osphena comes with a boxed warning in the form of Endometrial Cancer and Cardiovascular Disorders. Since Ospemifene is an ER agonist/antagonist with tissue selective effects. In endometrium, due to Ospemifene agonistic effects, there is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a <i>progestin</i> to estrogen therapy reduces the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. There is a reported increased risk of stroke and deep vein thrombosis in postmenopausal women who received daily oral conjugated estrogens alone therapy over 7.1 years. So, Ospemifene should be prescribed for the <i>shortest duration</i> consistent with treatment goals.</span></div>
<div class="separator" style="clear: both; text-align: justify;">
<span style="font-family: inherit;"><br /></span></div>
<div class="separator" style="clear: both;">
</div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;">Full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203505s000lbl.pdf">here</a>.</span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;"><br /></span></div>
<div class="separator" style="clear: both;">
<span style="font-family: inherit;">The license holder is <a href="http://www.shionogi.com/">Shionogi Inc.</a>, and the product website is <a href="http://www.osphena.com/">www.osphena.com</a>.</span></div>
</div>
